617 filings
Page 18 of 31
6-K
1s8hzeh 00c
16 Dec 16
Amended and Restated Credit Agreement and Guaranty
12:00am
6-K
g33f tqqpxjca5db
6 Dec 16
VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors
12:00am
6-K
ma6npg8
14 Nov 16
VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vacâ„¢ Hepatitis B Vaccine
12:00am
6-K
jwkriz
9 Nov 16
Condensed Consolidated Financial Statements
12:00am
6-K
78g0m9z9 wbnkd3
11 Oct 16
VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
12:00am
6-K
a2j5oc
26 Sep 16
Report of Voting Results
12:00am
6-K
d24lgjxu49
20 Sep 16
VBI Vaccines Completes Enrollment of Participants in the Phase I
12:00am
6-K
p7t 4zmk8v
23 Aug 16
Current report (foreign)
12:00am
6-K
aqhis4 591abz
22 Aug 16
Current report (foreign)
12:00am
6-K
nsarxpl
15 Aug 16
Condensed Consolidated Financial Statements
12:00am
EFFECT
9zssnd5ypf
5 Aug 16
Notice of effectiveness
12:00am
UPLOAD
6eqv2888p9hv27g
3 Aug 16
Letter from SEC
12:00am
CORRESP
4xfspv1bvwx3woln7fp
3 Aug 16
Correspondence with SEC
12:00am
6-K
ope k292ncnc
25 Jul 16
VBI Vaccines Appoints Dr. Francisco Diaz-Mitoma as Chief Medical Officer
12:00am
F-3
p4r0c
22 Jul 16
Shelf registration (foreign)
12:00am
6-K
8neyjv8 g71e4i0hv2i
19 Jul 16
VBI Vaccines Applies its eVLP Platform in the Development of a Novel Vaccine Candidate to Prevent Zika Virus
12:00am
D
idppmju pudsksc
5 Jul 16
$13.61M in equity, sold $13.61M, 3 investors
12:00am
6-K
r8hy0t
23 Jun 16
VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate
12:00am
S-8
m0b8n x8y
21 Jun 16
Registration of securities for employees
12:00am
6-K
ftq0aed6q5qd9
21 Jun 16
VBI Vaccines Announces Closing of $13.6 Million Private Placement
12:00am